Byrne CJ, Parton T, McWhinney B, et al. Population pharmacokinetics of total and unbound teicoplanin concentrations and dosing simulations in patients with haematological malignancy. J Antimicrob Chemother. 2018;73(4):995–1003.

Article  CAS  PubMed  Google Scholar 

Freifeld AG, Bow EJ, Sepkowitz KA, et al. Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 update by the Infectious Diseases Society of America. Clin Infect Dis. 2011;52(4):e56–93.

Article  PubMed  Google Scholar 

Infectious Diseases Society of Taiwan, Hematology Society of Taiwan, Medical Foundation in Memory Dr. Deh-Lin Cheng, Foundation of Professor Wei-Chuan Hsieh for Infectious Diseases Research and Education, CY Lee's Research Foundation for Pediatric Infectious Diseases and Vaccine. Guidelines for the use of antimicrobial agents in patients with febrile neutropenia in Taiwan. J Microbiol Immunol Infect. 2005;38(6):455–7.

Google Scholar 

Hanai Y, Takahashi Y, Niwa T, et al. Clinical practice guidelines for therapeutic drug monitoring of teicoplanin: a consensus review by the Japanese Society of Chemotherapy and the Japanese Society of Therapeutic Drug Monitoring. J Antimicrob Chemother. 2022;77(4):869–79.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Svetitsky S, Leibovici L, Paul M. Comparative efficacy and safety of vancomycin versus teicoplanin: systematic review and meta-analysis. Antimicrob Agents Chemother. 2009;53(10):4069–79.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Van der Auwera P, Aoun M, Meunier F. Randomized study of vancomycin versus teicoplanin for the treatment of gram-positive bacterial infections in immunocompromised hosts. Antimicrob Agents Chemother. 1991;35(3):451–7.

Article  PubMed  PubMed Central  Google Scholar 

Sako KI, Nakamaru Y, Ikawa K, et al. Population pharmacokinetics of teicoplanin and its dosing recommendations for neutropenic patients with augmented renal clearance for hematological malignancies. Ther Drug Monit. 2021;43(4):519–26.

Article  CAS  PubMed  Google Scholar 

Sato Y, Hiramatsu K, Suzuki Y, et al. Optimal trough concentration of teicoplanin in febrile neutropenic patients with hematological malignancy. Chemotherapy. 2018;63(1):29–34.

Article  PubMed  Google Scholar 

Byrne CJ, Roberts JA, McWhinney B, et al. Variability in trough total and unbound teicoplanin concentrations and achievement of therapeutic drug monitoring targets in adult patients with hematological malignancy. Antimicrob Agents Chemother. 2017;61(6):e02466-16.

Pea F. Teicoplanin and therapeutic drug monitoring: an update for optimal use in different patient populations. J Infect Chemother. 2020;26(9):900–7.

Article  CAS  PubMed  Google Scholar 

Wang JT, Liao HI, Wu Lin FL, Chang SC. Loading dose required to achieve rapid therapeutic teicoplanin trough plasma concentration in patients with multidrug-resistant gram-positive infections. Basic Clin Pharmacol Toxicol. 2012;110(5):416–20.

Article  CAS  PubMed  Google Scholar 

Ueda T, Takesue Y, Nakajima K, et al. High-dose regimen to achieve novel target trough concentration in teicoplanin. J Infect Chemother. 2014;20(1):43–7.

Article  CAS  PubMed  Google Scholar 

Byrne CJ, Egan S, Fennell JP, et al. Teicoplanin use in adult patients with haematological malignancy: exploring relationships between dose, trough concentrations, efficacy and nephrotoxicity. Int J Antimicrob Agents. 2015;46(4):406–12.

Article  CAS  PubMed  Google Scholar 

Kim SH, Kang CI, Huh K, et al. Evaluating the optimal dose of teicoplanin with therapeutic drug monitoring: not too high for adverse event, not too low for treatment efficacy. Eur J Clin Microbiol Infect Dis. 2019;38(11):2113–20.

Article  CAS  PubMed  Google Scholar 

Ramos-Martin V, Johnson A, McEntee L, et al. Pharmacodynamics of teicoplanin against MRSA. J Antimicrob Chemother. 2017;72(12):3382–9.

Article  CAS  PubMed  Google Scholar 

Hu S, Wang T, You H, et al. Therapeutic drug monitoring of teicoplanin in haematological malignancy patients with febrile neutropenia and optimizing dosage regimens. Basic Clin Pharmacol Toxicol. 2018;123(5):594–601.

Article  CAS  PubMed  Google Scholar 

Chen GJ, Lin SW, Tsai IL, Kuo CH, Wang JT, Hsieh SM. Therapeutic drug monitoring of the teicoplanin trough level after the loading doses in patients receiving venoarterial extracorporeal membrane oxygenation. J Formos Med Assoc. 2020;119(6):1086–92.

Article  CAS  PubMed  Google Scholar 

Tsai IL, Sun HY, Chen GY, Lin SW, Kuo CH. Simultaneous quantification of antimicrobial agents for multidrug-resistant bacterial infections in human plasma by ultra-high-pressure liquid chromatography-tandem mass spectrometry. Talanta. 2013;116:593–603.

Article  CAS  PubMed  Google Scholar 

Zhou L, Gao Y, Cao W, et al. Retrospective analysis of relationships among the dose regimen, trough concentration, efficacy, and safety of teicoplanin in Chinese patients with moderate-severe Gram-positive infections. Infect Drug Resist. 2018;11:29–36.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Matthews PC, Chue AL, Wyllie D, et al. Increased teicoplanin doses are associated with improved serum levels but not drug toxicity. J Infect. 2014;68(1):43–9.

Article  PubMed  Google Scholar 

Pea F, Viale P, Candoni A, et al. Teicoplanin in patients with acute leukaemia and febrile neutropenia: a special population benefiting from higher dosages. Clin Pharmacokinet. 2004;43(6):405–15.

Article  CAS  PubMed  Google Scholar 

Saito K, Kamio S, Ito K, Suzuki N, Abe K, Goto T. A simple scoring method to predict augmented renal clearance in haematologic malignancies. J Clin Pharm Ther. 2020;45(5):1120–6.

Article  CAS  PubMed  Google Scholar 

Roberts JA, Pea F, Lipman J. The clinical relevance of plasma protein binding changes. Clin Pharmacokinet. 2013;52(1):1–8.

Article  CAS  PubMed  Google Scholar 

Ulldemolins M, Roberts JA, Rello J, Paterson DL, Lipman J. The effects of hypoalbuminaemia on optimizing antibacterial dosing in critically ill patients. Clin Pharmacokinet. 2011;50(2):99–110.

Article  CAS  PubMed  Google Scholar 

Barbot A, Venisse N, Rayeh F, Bouquet S, Debaene B, Mimoz O. Pharmacokinetics and pharmacodynamics of sequential intravenous and subcutaneous teicoplanin in critically ill patients without vasopressors. Intensive Care Med. 2003;29(9):1528–34.

Article  CAS  PubMed  Google Scholar 

Yamada T, Nonaka T, Yano T, et al. Simplified dosing regimens of teicoplanin for patient groups stratified by renal function and weight using Monte Carlo simulation. Int J Antimicrob Agents. 2012;40(4):344–8.

Article  CAS  PubMed  Google Scholar 

Seki M, Yabuno K, Miyawaki K, Miwa Y, Tomono K. Loading regimen required to rapidly achieve therapeutic trough plasma concentration of teicoplanin and evaluation of clinical features. Clin Pharmacol. 2012;4:71–5.

CAS  PubMed  PubMed Central  Google Scholar 

Wei X, Zhao M, Xiao X. Optimization of dosing regimens of vancomycin, teicoplanin, linezolid and daptomycin against methicillin-resistant Staphylococcus aureus in neutropenic patients with cancer by Monte Carlo simulations. J Chemother. 2021;33(8):547–53.

Article  CAS  PubMed  Google Scholar 

Hirai T, Hosohata K, Ogawa Y, Iwamoto T. Clinical predictors of nephrotoxicity associated with teicoplanin: meta-analysis and meta-regression. Basic Clin Pharmacol Toxicol. 2022;130(1):110–21.

Article  CAS  PubMed  Google Scholar 

Bernareggi A, Cavenaghi L, Assandri A. Pharmacokinetics of [14C]teicoplanin in male rats after single intravenous dose. Antimicrob Agents Chemother. 1986;30(5):733–8.

Article  CAS  PubMed  PubMed Central  Google Scholar